The National Health Insurance Service disclosed drugs subject to monitoring for Type A and Type B of the Price-Volume Agreement negotiations in the fourth quarter of 2022.

The list is attracting attention as Yuhan Corp’s novel non-small-cell lung cancer drug Leclaza was also selected for monitoring, as well as domestic homegrown drugs such as Kanarb, Supect, and Pelubi.

A total of 91 drugs that are subject to monitoring for PVA negotiations in the 4th quarter this year were disclosed in advance on NHIS’s webpage on the 20th.

The NHIS selects drugs that are subject to monitoring for PVA Type A and B negotiations every quarter.

Drugs receive negotiations u